



Actinogen Medical

ASX ANNOUNCEMENT

Results of Annual General Meeting

The Company held an Annual General Meeting today, 30 November 2016 at 11.00am (AEDT).

The resolutions voted were in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

Further information, required by Section 251AA(2) of the Corporations Act 2001 (Cth), is attached.

Yours faithfully

Peter Webse
Company Secretary

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer's disease.

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the second leading cause of death in Australia, behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease.

Results of Annual General Meeting

30 November 2016

RESOLUTION		Proxy and Direct Votes Lodged as at Proxy Close				Number of Votes Cast in Person or by Proxy on a Poll		
		For	Against	Discretionary	Abstain	For	Against	Abstain
1	Adoption of remuneration report	219,666,219	1,137,843	29,543,160	218,130	Passed on a Show of Hands	Passed on a Show of Hands	Passed on a Show of Hands
2	Approval of 10% Placement Capacity	288,144,189	673,178	41,929,554	642,450	Passed on a Show of Hands	Passed on a Show of Hands	Passed on a Show of Hands
3	Re-election of Director – Dr Jason Loveridge	289,292,332	37,250	41,960,554	99,235	Passed on a Show of Hands	Passed on a Show of Hands	Passed on a Show of Hands
4	Renewal of Proportional Takeover Provisions in Constitution	288,506,837	338,030	41,956,554	587,950	Passed on a Show of Hands	Passed on a Show of Hands	Passed on a Show of Hands
5	Extension of time to repay loan to the Company by Mr Martin Rogers	250,759,115	2,017,042	42,043,369	161,951	Passed on a Show of Hands	Passed on a Show of Hands	Passed on a Show of Hands

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the above statistics are provided in respect of each resolution on the Notice of Meeting

Note - Abstention votes are not counted in computing the required majority on a poll